Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases... Show more
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing immunomodulation therapies delivered through alternative routes of administration. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to stimulate regulatory T cells and dampen neuroinflammation. The company is pursuing foralumab primarily in non-active secondary progressive multiple sclerosis (na-SPMS), while also evaluating it in Phase 2 trials for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). Because na-SPMS has no FDA-approved disease-modifying treatment, Tiziana occupies a distinct position in an underserved therapeutic area, which is why investors track its clinical milestones closely.
Over the last 30 days, TLSA declined from a closing level of about $1.01 to roughly $0.63, a drop of approximately 38%. The most pronounced move occurred in early November, when the stock fell sharply on elevated volume following the company's Phase 2a INFORM-MS data release. The decline was not uniform: shares staged periodic rebounds in mid-November as management presented additional context, but remained well below their late-October levels.
The quarterly picture tells a similar, slightly steeper story. Compared with levels around $1.12–$1.14 seen in mid-to-late August, the stock is down roughly 44% over the trailing quarter. This reflects a broader pattern of pressure through September and October, punctuated by the November data catalyst that crystallized investor concerns about the program's next steps.
The primary catalyst was the topline readout from the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS. The study met its dual primary endpoints for the 50 μg dose, including a statistically significant reduction in microglial activation as measured by TSPO PET imaging (p=0.0168), along with a favorable safety and tolerability profile. However, the exploratory 100 μg dose did not demonstrate the same efficacy signal, leaving investors uncertain about dose selection and the path toward a pivotal trial.
Secondary measures added nuance to the picture. Clinically meaningful and statistically significant improvements in fatigue were observed in both dose arms relative to baseline, while the placebo group showed no significant change. Despite these encouraging signals, the higher-dose miss weighed on sentiment, and shares sold off sharply on elevated volume as the market digested the mixed results. Management subsequently hosted a Key Opinion Leader call and presented at the Jefferies Healthcare Conference, reiterating plans to discuss next steps with the FDA.
Over the trailing quarter, Tiziana's shares were shaped by the anticipation and eventual delivery of key clinical milestones. Through September and October, the company completed final dosing and last patient visits in the INFORM-MS trial and began dosing participants in its ALS BANYAN study, keeping the stock tethered to the timing and interpretation of data readouts. The early-November topline announcement then became the defining event, converting months of pre-readout positioning into a decisive repricing. The broader context of a small-cap, pre-revenue biotech with a binary pipeline left the stock especially sensitive to the nuance of the data, including the mixed dose-response outcome.
Tickeron's Trending AI Robots page showcases a curated selection of automated trading bots from a platform that offers hundreds of AI-driven strategies across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a focused view of strategies that are currently generating attention. These bots vary widely in their approach, holding timeframe, and performance metrics, so investors can compare different styles rather than relying on a single methodology. Exploring the page can help traders identify quantitative signals and diversification tools that align with their own objectives.
Looking ahead, the most important factor is the FDA's response to the INFORM-MS results and any guidance the company provides on a potential pivotal trial design and dose selection. Investors will also monitor the full dataset presentation at an upcoming scientific meeting, as well as progress across foralumab's other Phase 2 programs in Alzheimer's disease, ALS, and multiple system atrophy. As a pre-revenue biotech, Tiziana's cash runway and any future financing activity remain key considerations. Clinical trial outcomes, regulatory interactions, and financing decisions are inherently uncertain, and investors should evaluate these risks carefully rather than relying on any single forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
On November 18, 2026, the Stochastic Oscillator for TLSA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 59 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLSA's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on TLSA as a result. In 82 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TLSA just turned positive on November 18, 2026. Looking at past instances where TLSA's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
Following a +40.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLSA advanced for three days, in 203 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
TLSA moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TLSA crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
TLSA broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TLSA entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. TLSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.834) is normal, around the industry mean (3.596). P/E Ratio (-4.052) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biotechnology company
Industry Biotechnology